Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2022-08-24 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
独立董事关于公司第七届董事会第二十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Anhui Anke Biotechnology (Group) Co., Ltd. regarding the company's third restricted stock incentive plan and its implementation assessment management measures. It discusses compliance with relevant laws and regulations, the qualifications of incentive recipients, and the governance and performance assessment related to the stock incentive plan. There is no financial data, earnings information, or report publication announcement. The document is a formal opinion related to governance and management decisions about stock incentives, which fits best under Board/Management Information (MANG) as it relates to management-level decisions and governance matters rather than a full report or announcement.
2022-08-24 Chinese
创业板上市公司股权激励计划自查表
Regulatory Filings Classification · 95% confidence The document is a detailed compliance checklist related to a stock incentive plan for a listed company, including regulatory compliance, eligibility, performance metrics, and procedural adherence. It does not contain financial statements or earnings data, nor is it an announcement or presentation. It is a regulatory compliance self-inspection form related to equity incentive plans, which does not fit into financial reports, earnings releases, or management reports. It is not a report publication announcement since it contains substantive content rather than a brief notice. The best fitting category is Regulatory Filings (RNS) as a general compliance document that does not fit other specific categories.
2022-08-24 Chinese
第三期限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as an implementation and assessment management method for a restricted stock incentive plan by the company's board. It details the performance evaluation criteria, assessment principles, scope, and procedures related to the stock incentive plan for directors, senior management, and key personnel. There is no financial statement data, earnings results, or regulatory filings such as audit reports or annual reports. Instead, it focuses on governance and management of stock incentives and performance assessments tied to company and individual performance. This aligns with governance-related information about internal rules and management practices rather than financial reporting or announcements. Therefore, the document best fits the category of Governance Information (CGR). The document length is under 5,000 characters but contains substantive content, so it is not a mere announcement (RPA).
2022-08-24 Chinese
第三期限制性股票激励计划（草案）
Board/Management Information Classification · 95% confidence The document is titled "安徽安科生物工程（集团）股份有限公司第三期限制性股票激励计划（草案）" which translates to "Anhui Anke Biological Engineering (Group) Co., Ltd. Third Restricted Stock Incentive Plan (Draft)". The content extensively discusses the details of a restricted stock incentive plan, including the number of shares, allocation, eligibility, pricing, vesting periods, and legal compliance. It is a detailed plan document outlining the company's stock incentive scheme for employees and management. This type of document is related to management and board decisions about stock incentives and executive compensation plans. It is not an announcement of voting results, not a financial report, nor a regulatory filing about earnings or dividends. It is not a proxy statement or remuneration report but a detailed incentive plan. Therefore, the most appropriate classification is "Board/Management Information (MANG)" as it relates to management decisions and plans regarding stock incentives for executives and employees.
2022-08-24 Chinese
安徽安科生物工程(集团)股份有限公司2022年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised through a non-public stock issuance by 安徽安科生物工程（集团）股份有限公司 for the half-year period ending June 30, 2022. It references regulatory guidelines from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, includes detailed financial figures on fundraising, usage, interest income, and bank accounts, and discusses compliance with relevant laws and regulations. The document is titled as a "专项报告" (special report) on the half-year fundraising funds usage and storage situation. It is not a full annual or interim financial report but a specific report on fundraising capital management and usage. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length is over 5,000 characters and contains substantive financial data related to fundraising usage, not just an announcement or certification. Therefore, the best classification is CAP with high confidence.
2022-08-24 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2022 年半年度报告摘要" which translates to "2022 Semi-Annual Report Summary". It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also discusses business performance, R&D progress, patents, and other operational details for the half-year period. The length of the document (8424 characters) and the presence of substantive financial and operational data indicate this is a comprehensive interim report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-24 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.